SML1887
APX2009
≥98% (HPLC)
别名:
(2E)-2-[(3-methoxy-1,4-dioxo-1,4-dihydronaphthalen-2-yl)methylidene]-N,N-diethylpentanamide, 2-[(1,4-Dihydro-3-methoxy-1,4-dioxo-2-naphthalenyl)methylene]-N,N-diethyl-pentanamide
产品名称
APX2009, ≥98% (HPLC)
InChI
1S/C21H25NO4/c1-5-10-14(21(25)22(6-2)7-3)13-17-18(23)15-11-8-9-12-16(15)19(24)20(17)26-4/h8-9,11-13H,5-7,10H2,1-4H3/b14-13+
InChI key
WEMXCNYTFZUFSB-BUHFOSPRSA-N
SMILES string
O=C1C(OC)=C(/C=C(CCC)/C(N(CC)CC)=O)C(C2=C1C=CC=C2)=O
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 10 mg/mL, clear
storage temp.
2-8°C
Quality Level
Biochem/physiol Actions
APX2009 is a cell penetrant potent and selective second-generation inhibitor of APE1 redox-signaling that stimulates APE1 DNA repair activity. APX2009 is neuroprotective against cisplatin and oxaliplatin induced toxicity. APX2009 exhibits potent antitumor activity in neuroblastoma cell lines and 3D spheroid pancreatic tumor model.
Cell penetrant potent and selective second-generation inhibitor of APE1 redox-signaling that stimulates APE1 DNA repair activity
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Mark R Kelley et al.
The Journal of pharmacology and experimental therapeutics, 359(2), 300-309 (2016-10-21)
Chemotherapy-induced peripheral neuropathy (CIPN) is a potentially debilitating side effect of a number of chemotherapeutic agents. There are currently no U.S. Food and Drug Administration-approved interventions or prevention strategies for CIPN. Although the cellular mechanisms mediating CIPN remain to be
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持